Zingerone Based Green Synthesized Sodium Doped Zinc Oxide Nanoparticles Eliminate U87 Glioblastoma Cells by Inducing Apoptosis Publisher Pubmed



S Parsaei SAMAN ; H Yaghoobi HAJAR ; P Beshkar PEZHMAN ; Ha Khonakdar Hossein ALI ; Mr Khosravi Farsani Mohammad REZA ; O Safari OMID
Source: Scientific Reports Published:2025

Abstract

Grade IV astrocytoma, also referred to as glioblastoma (GBM), is the most common type of glioma, accounting for over 60% of all brain tumors. It is still a fatal illness in spite of years of investigation and does not currently have a treatment. Thus, scientists and medical professionals are constantly trying to understand the molecular processes and heterogeneity of GBM as well as looking for new ways to improve treatment results. Numerous studies have indicated that nanomaterials, and more especially nanoparticles, offer a great deal of potential for killing cancer cells; as a result, they are being considered as a potential alternative cancer treatment. Several studies have demonstrated that ZnO NPs have shown specific cytotoxicity against cancer cells while leaving normal cells unharmed. In this study we aim to synthesize sodium doped zinc oxide NPs using zingerone in an environmentally friendly manner to evaluate their cytotoxic effects on U87 GBM cell line and normal HEK cell line and investigate the occurrence of apoptosis via apoptosis assay by flowcytometry and gene expression study of TP53 and related genes to apoptosis and cell cycle regulation pathways. It was demonstrated that Na-doped ZnO NPs had a significant cytotoxic effect on U87 cells while having significantly less effect on normal HEK cells. Na-doped ZnO NPs eliminated cancerous cells through apoptosis induction and possibly cell cycle regulation via up-regulation of TP53, PTEN, BAX, P21 and down-regulation of Bcl2. The unique physicochemical properties of nanoparticles turn them into fascinating agents to treat GBM. Hence, the necessity of exploring the vast, yet unknown field of nanoparticles potentials cannot be over looked. © 2025 Elsevier B.V., All rights reserved.